The Bayou City knows energy. Silicon Valley knows tech. But each can't only invest in what they know. Getty Images

There's an adage in investing that you should only invest in what you know. Generally speaking, this is a good rule — if you do not understand a company product or have no experience with its industry, then investing in a specific company could be risky. Yet, there are times when it's necessary to get out of your comfort zone and try something new and adventurous. The challenge is determining how to do that.

We are financial advisors from Houston and San Francisco, and we frequently do just that — encourage our clients to explore investments out of their comfort zones.

In Houston, we understand energy. As of 2017, Texas accounted for 37 percent of the nation's crude oil production and 24 percent of its natural gas production. And as of January 2018, Texan oil refineries accounted for 31 percent of the nation's refining capacity — and that is just oil. In 2017, Texas lead the country in wind-generated electricity and generated a quarter of all wind power in the US. It is safe to say, we feel comfortable talking the language and investing in the energy industry. Whether it is machinery fabrication for upstream, construction of pipes for midstream, or refining downstream, some Texans are comfortable investing in these areas.

In San Francisco, we understand tech, whether it involves social media, silicon, or apps. We have five of the top 10 most prominent tech companies in the world. In 2018, the technology industry accounted for around 62 percent of all office leasing activity in San Francisco. The Bay Area also dominates venture capital investment, accounting for 45 percent of all capital investment in the U.S, in large part because of tech startups in the area.

Naturally, we see that some investors in our hometowns feel comfortable investing extensively in these two industries. Sometimes, these investments take the form of venture capital, other times they are individual stocks.

For Houstonians, allocating all of their investments to the energy industry carries too much risk should the energy industry falter. The same is true for San Francisco with venture capital and technology.

Therefore, we encourage investors to diversify their portfolios by placing funds in multiple vehicles and equities with the knowledge that different industries will react differently to market ups and downs. While there is never a guarantee of the outcome, diversification is one of many factors critical to long-term investment success.

For Houstonians and San Franciscans, there are other industries we understand in which we can invest. For example, Houston boasts the largest medical center in the world with roughly 361,000 people employed in the healthcare industry. While San Francisco employs roughly 277,500 in tourism. If you're looking to diversify your portfolio, look around to see the opportunities in which other people are investing. You may be surprised about what you learn, and ultimately how comfortable you can become investing in industries you may be unfamiliar.

We do not recommend ever investing in a product or industry that you have no understanding of at all. However, if you have excitement about an investment opportunity and feel there is potential for growth to your portfolio, your investment may prove fruitful in the future. Still, please seek out a financial advisor to help.

------

Joseph Radzwill is senior vice president and financial adviser with the Wealth Management Division of Morgan Stanley in Houston. Victoria Bailey is a financial adviser with the Wealth Management Division of Morgan Stanley in San Francisco.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”